Retrospective Experience Of CIED Implantation
Retrospective Experience of CIED Implantation With Piedmont Athens Regional Electrophysiology
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Georgia
-
Athens, Georgia, United States, 30606
- Piedmont Athens Electrophysiology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Any patient that had a CIED implanted with either a CanGaroo Envelope, a TYRX Envelope, or no envelope on or after March 27, 2017
Exclusion Criteria:
- Any patient that had a CIED implanted with any other type of envelope
- Any patient that had a CIED implanted prior to March 27, 2017
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
CanGaroo Envelope
Patients who received a CanGaroo Envelope with their Cardiac Implantable Electronic Device (CIED) implantation.
|
CanGaroo Envelope with Cardiac Implantable Electronic Device (CIED) implantation
|
|
TYRX Envelope
Patients who received a TYRX Envelope with their Cardiac Implantable Electronic Device (CIED) implantation.
|
TYRX Envelope with Cardiac Implantable Electronic Device (CIED) implantation
|
|
No Envelope
Patients who had their Cardiac Implantable Electronic Device (CIED) implanted with no envelope.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Major Infection Post Procedure
Time Frame: 12 months post procedure
|
Major CIED infections are defined as a CIED infection resulting in one or more of the following:
|
12 months post procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Pocket Related Issues Prompting an Office Visit
Time Frame: 12 months post procedure
|
Any pocket related issues that prompted an office visit
|
12 months post procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Jerome Riebman, MD, Aziyo Biologicgs, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CPR-2212
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.